THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [11.23] ID: TIP-MED-000227 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Quetiapine Fumarate (Second-Generation Antipsychotic)

Active Ingredient / Scientific Identity: Quetiapine Fumarate • Class: Second-Generation (Atypical) Dibenzothiazepine Antipsychotic & Mood Stabiliser

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Quetiapine Fumarate (Second-Generation Antipsychotic) ([11.23] | ID: TIP-MED-000227) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/11-23-quetiapine-fumarate-second-generation-antipsychotic/
Generic / Entity NameQuetiapine Fumarate (Second-Generation Antipsychotic) ([11.23])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSecond-Generation (Atypical) Dibenzothiazepine Antipsychotic & Mood Stabiliser
Available Dosage FormsImmediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Quetiapine Fumarate (Second-Generation Antipsychotic) (TIP-MED-000227, Reference Code [11.23]) is classified under CNS & Psychiatric Medicines (Ch 11) as a Second-Generation (Atypical) Dibenzothiazepine Antipsychotic & Mood Stabiliser. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.23], p. 151): Qutan, Quel, Seroquel, Q-Pin — Strengths & Dosage Forms: Immediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.23], p. 151): Qutan, Quel, Seroquel, Q-Pin — Strengths & Dosage Forms: Immediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.
Dosage Forms & Available Strengths:
Immediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Transient 'hit-and-run' loose binding to striatal D2 receptors with stronger antagonism at 5-HT2A, H1 (low-dose sedation), alpha-1 adrenergic, and active metabolite norquetiapine 5-HT1A/NET sites.

4. Therapeutic Indications & Evidence-Supported Uses

  • Schizophrenia
  • bipolar I/II acute mania, bipolar depression, and maintenance
  • adjunctive treatment in major depressive disorder

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Bipolar Depression: Start 50 mg HS Day 1 -> 100 mg Day 2 -> 200 mg Day 3 -> 300 mg HS Day 4. Schizophrenia / Mania: Titrate from 50-100 mg/day to 400-800 mg/day. • Paediatric: Bipolar Mania (>=10 yr) / Schizophrenia (>=13 yr): Start 25 mg BD, titrate to 400-600 mg/day.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.
Elimination & Renal Adjustment:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.
Hepatic Impairment Considerations:
Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Concomitant strong CYP3A4 inhibitors (Ketoconazole, Itraconazole, Ritonavir). • Precautions: Least extrapyramidal risk among antipsychotics (preferred in Parkinson's psychosis alongside clozapine), but causes orthostatic hypotension, metabolic syndrome (hyperglycaemia/dyslipidaemia), and cataracts.

Key Clinical Precautions: Renal: No dose adjustment required in renal impairment. • Hepatic: Hepatic impairment: Start at 25 mg/day and titrate slowly in 25-50 mg increments.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Somnolence, postural dizziness, dry mouth, weight gain, constipation, mild T4 reduction.
  • Hyperglycaemia/new-onset diabetes, dyslipidaemia, QT prolongation, neuroleptic malignant syndrome.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Phenytoin / Carbamazepine -> increase quetiapine clearance 5-fold (reduces efficacy); Ketoconazole / Clarithromycin -> toxic accumulation; Antihypertensives -> orthostatic syncope

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Take bedtime doses before sleep; rise slowly from sitting/lying to avoid dizziness; swallow SR/XR tablets whole on an empty stomach or light meal.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release Tablet: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg; Extended-Release (SR/XR) Tablet: 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.23] (p. 151)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/11-23-quetiapine-fumarate-second-generation-antipsychotic/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.